Presented At:
Cancer Research & Oncology 2018
Presented By:
Karin Rodland, PhD - Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory
Speaker Biography:
Dr. Karin Rodland joined the Biological Sciences Division at the Pacific Northwest National Laboratory in October 2001, after serving seventeen years on the faculty of Oregon Health Sciences University. As Chief Scientist for Biomedical Research at PNNL, she has promoted the application of PNNL's traditional strengths in mass spectrometry, proteomics, and systems biology to important problems in biomedical research. She is currently the PNNL co-Director of the OHSU-PNNL Precision Medicine Innovation CoLaboratory, a joint effort dedicated to improving patient outcomes through the integration of cutting edge technologies in integrated omics, imaging, and data analysis to advance the goals of precision medicine. Dr. Rodland's own research focuses on signal transduction pathways that regulate proliferation in normal and malignant cells. She was the first to recognize the role of the calcium-sensing receptor in modulating proliferation in response to small molecules in the extracellular environment. Since joining PNNL, she has adopted a systems biology approach to signal transduction and has become a recognized expert in the field of proteomics and cancer biomarkers.
Webinar:
Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy
Webinar Abstract:
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. Proteogenomics represents a fusion of those two approaches, leveraging the strengths of each to provide a more integrated vision of the flow of information from DNA to RNA to protein and eventually function at the molecular level. Proteogenomic studies have been incorporated into multiple activities associated with precision oncology, demonstrating substantial added value. Innovative study designs integrating genomic, transcriptomic and proteomic data, particularly those using clinically relevant samples and involving clinical trials, are poised to provide new insights regarding cancer risk, progression, and response to therapy.
Learning Objectives:
1. Understand the value-added of including protein measurements with genomics and transcriptomics
2. Understand the importance of pathway-level analysis
Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots ([ Ссылка ])
2. Watch the webinar on YouTube above or on the LabRoots Website ([ Ссылка ])
3. Click Here to get your PACE (Expiration date – October 10, 2020 07:30 AM) – [ Ссылка ]
LabRoots on Social:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Instagram: [ Ссылка ]
Pinterest: [ Ссылка ]
SnapChat: labroots_inc
